PHARMExcel are delighted to have be selected as INmuneBio’s U.K. CRO to lead on their Phase I clinical trial of INKmune, a novel therapy to prime the patient’s own Natural Killer (NK) cells to attack their cancer, in patients with high-risk Myelodysplastic Syndrome (MDS) (EUDRACT 2019-004820-40). This is a single center, Phase I trial and will be the first-in-man study using INKmune. PHARMExcel have been pivotal, despite the COVID 19 challenges, in achieving UK regulatory and Ethics approval for the study and will now support the company to commence the conduct of the study.